These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 6097267)

  • 1. Pharmacological properties of the new orally active angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl] -(1S,3S,5S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498).
    Becker RH; Schölkens BA; Metzger M; Schulze KJ
    Arzneimittelforschung; 1984; 34(10B):1411-6. PubMed ID: 6097267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of angiotensin converting enzyme by 2-[N-[(S)-1-carboxy-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2-azabicyclo [3.3.0]octane-3-carboxylic acid (Hoe 498 diacid). Comparison with captopril and enalaprilat.
    Bünning P
    Arzneimittelforschung; 1984; 34(10B):1406-10. PubMed ID: 6097266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular and antihypertensive activities of the novel non-sulfhydryl converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498).
    Schölkens BA; Becker RH; Kaiser J
    Arzneimittelforschung; 1984; 34(10B):1417-25. PubMed ID: 6097268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498): antihypertensive action and persistent inhibition of tissue converting enzyme activity in spontaneously hypertensive rats.
    Unger T; Fleck T; Ganten D; Lang RE; Rettig F
    Arzneimittelforschung; 1984; 34(10B):1426-30. PubMed ID: 6097269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S) -2-azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498)--a new and highly effective angiotensin I converting enzyme inhibitor.
    Metzger H; Maier R; Sitter C; Stern HO
    Arzneimittelforschung; 1984; 34(10B):1402-6. PubMed ID: 6097265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis of a highly active angiotensin converting enzyme inhibitor: 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498).
    Teetz V; Geiger R; Henning R; Urbach H
    Arzneimittelforschung; 1984; 34(10B):1399-401. PubMed ID: 6097264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerance and pharmacodynamics of the angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498) in healthy volunteers.
    Witte PU; Metzger H; Eckert HG; Irmisch R
    Arzneimittelforschung; 1984; 34(10B):1448-51. PubMed ID: 6097272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the new oral angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498) in essential hypertension.
    Felder K; Witte PU
    Arzneimittelforschung; 1984; 34(10B):1452-4. PubMed ID: 6097273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and biotransformation of 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S, 5S)-2-azabicyclo [3.3.0]octane-3-carboxylic acid (Hoe 498) in rat, dog and man.
    Eckert HG; Badian MJ; Gantz D; Kellner HM; Volz M
    Arzneimittelforschung; 1984; 34(10B):1435-47. PubMed ID: 6097271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo.
    Gross DM; Sweet CS; Ulm EH; Backlund EP; Morris AA; Weitz D; Bohn DL; Wenger HC; Vassil TC; Stone CA
    J Pharmacol Exp Ther; 1981 Mar; 216(3):552-7. PubMed ID: 6259322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. General pharmacology of ramipril.
    Omosu M; Komine I; Becker RH; Schölkens BA
    Arzneimittelforschung; 1988 Sep; 38(9):1309-17. PubMed ID: 2975947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498) and its hydrolysis product in serum and urine.
    Hajdú P; Schmidt D; Bomm M; Hack L; Keller A
    Arzneimittelforschung; 1984; 34(10B):1431-5. PubMed ID: 6097270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin-converting enzyme inhibitory activity of SCH 31846, a new non-sulfhydryl inhibitor.
    Sybertz EJ; Baum T; Ahn HS; Nelson S; Eynon E; Desiderio DM; Pula K; Becker F; Sabin C; Moran R; Vander Vliet G; Kastner B; Smith E
    J Cardiovasc Pharmacol; 1983; 5(4):643-54. PubMed ID: 6193364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute, subchronic and chronic toxicity of the new angiotensin converting enzyme inhibitor ramipril.
    Donaubauer HH; Mayer D
    Arzneimittelforschung; 1988 Jan; 38(1):14-20. PubMed ID: 2966628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of the new angiotensin converting enzyme inhibitor ramipril on several models of acute inflammation and the adjuvant arthritis in the rat.
    Caspritz G; Alpermann HG; Schleyerbach R
    Arzneimittelforschung; 1986 Nov; 36(11):1605-8. PubMed ID: 3028436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A radioimmunoassay for the angiotensin converting enzyme inhibitor ramipril and its active metabolite.
    Eckert HG; Münscher G; Oekonomopulos R; Strecker H; Urbach H; Wissmann H
    Arzneimittelforschung; 1985; 35(8):1251-6. PubMed ID: 3000393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Met5-enkephalin-Arg6-Phe7 degradation by inhibitors of dipeptidyl carboxypeptidase.
    Mellstrom B; Iadarola MJ; Yang HY; Costa E
    J Pharmacol Exp Ther; 1986 Oct; 239(1):174-8. PubMed ID: 2945003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of peptidase inhibitors on [Met5]enkephalin-Arg6-Phe7 and [Met5]enkephalin-Arg6-Gly7-Leu8-induced antinociception.
    Mellstrom B; Iadarola MJ; Costa E
    Eur J Pharmacol; 1987 Jan; 133(2):185-90. PubMed ID: 2949992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors: a comparison of captopril, enalapril, and HOE 498.
    van Gilst WH; de Graeff PA; Wesseling H; de Langen CD
    J Cardiovasc Pharmacol; 1986; 8(4):722-8. PubMed ID: 2427810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humoral and blood pressure effects of the angiotensin converting enzyme inhibitor ramipril in essential hypertension.
    Lenz T; Distler A; Haller H; Meyer-Sabellek W; Wilp C; Tansey MJ; Eckert HG; Metzger H; Irmisch R; Philipp T
    Arzneimittelforschung; 1986 Nov; 36(11):1693-6. PubMed ID: 3028438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.